Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 178

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A Magnetic Resonance Imaging–Based Prediction Model for Prostate Biopsy Risk Stratification

Open access
Mehralivand, Sherif, Shih, Joanna H., Rais-Bahrami, Soroush, Oto, Aytekin, Bednarova, Sandra, Nix, Jeffrey W., Thomas, John V., Gordetsky, Jennifer B., Gaur, Sonia, Harmon, Stephanie A., Siddiqui, Mohummad Minhaj, Merino, Maria J., Parnes, Howard L., Wood, Bradford J., Pinto, Peter A., Choyke, Peter L., Turkbey, Baris · 2018 · JAMA Oncology

Abstract

Importance: Multiparametric magnetic resonance imaging (MRI) in conjunction with MRI-transrectal ultrasound (TRUS) fusion-guided biopsies have improved the detection of prostate cancer. It is unclear whether MRI itself adds additional value to multivariable prediction models based on clinical parameters. Objective: To determine whether an MRI-based prediction model can reduce unnecessary biopsies in patients with suspected prostate cancer. Design, Setting, and Participants: Patients underwent MRI, MRI-TRUS fusion-guided biopsy, and 12-core systematic biopsy in 1 session. The development cohort used to derive the prediction model consisted of 400 patients from 1 institution enrolled between May 14, 2015, and August 31, 2016, and the validation cohort included 251 patients from 2 independent institutions who underwent biopsies between April 1, 2013, and June 30, 2016, at 1 institution and between July 1, 2015, and October 31, 2016, at the other institution. The MRI model included MRI-derived parameters in addition to clinical variables. Area under the curve of receiver operating characteristic curves and decision curve analysis were performed. Main Outcomes and Measures: Risk of clinically significant prostate cancer on biopsy, defined as a Gleason score of 3 + 4 or higher in at least 1 biopsy core. Results: Overall, 193 (48.3%) of the 400 patients in the development cohort (mean [SD] age at biopsy, 64.3 [7.1] years) and 96 (38.2%) of the 251 patients in the validation cohort (mean [SD] age at biopsy, 64.9 [7.2] years) had clinically significant prostate cancer, defined as a Gleason score greater than or equal to 3 + 4. By applying the model to the external validation cohort, the area under the curve increased from 64% to 84% compared with the baseline model (P < .001). At a risk threshold of 20%, the MRI model had a lower false-positive rate than the baseline model (46% [95% CI, 32%-66%] vs 92% [95% CI, 70%-100%]), with only a small reduction in the true-positive rate (89% [95% CI, 85%-96%] vs 99% [95% CI, 89%-100%]). Eighteen of 100 fewer biopsies could have been performed, with no increase in the number of patients with missed clinically significant prostate cancers. Conclusions and Relevance: The inclusion of MRI-derived parameters in a risk model could reduce the number of unnecessary biopsies while maintaining a high rate of diagnosis of clinically significant prostate cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2017.5667

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 178

Metadata

Authors
Mehralivand, S., Shih, J. H., Rais-Bahrami, S., Oto, A., Bednarova, S., Nix, J. W., Thomas, J. V., Gordetsky, J. B., Gaur, S., Harmon, S. A., Siddiqui, M. M., Merino, M. J., Parnes, H. L., Wood, B. J., Pinto, P. A., Choyke, P. L., & Turkbey, B.
Venue
JAMA Oncology
Published
2018-05-01
Volume
4
Issue
5
Pages
678
ISSN
2374-2437 (ISSN-L)
OpenAlex
W2789982652
Cited by
178
References
2
FWCI
15.05
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Magnetic Resonance Imaging–Based Prediction Model for Prostate Biopsy Risk Stratification. https://app.cochat.ai/papers/10.1001/jamaoncol.2017.5667
The paper
Mehralivand, S., Shih, J. H., Rais-Bahrami, S., Oto, A., Bednarova, S., Nix, J. W., Thomas, J. V., Gordetsky, J. B., Gaur, S., Harmon, S. A., Siddiqui, M. M., Merino, M. J., Parnes, H. L., Wood, B. J., Pinto, P. A., Choyke, P. L., & Turkbey, B. (2018). A Magnetic Resonance Imaging–Based Prediction Model for Prostate Biopsy Risk Stratification. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2017.5667

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.